{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2015"],"condition":["Oxaliplatin","Peripheral Nervous System Diseases","Colorectal neoplasms","OxaliplatinColorectal cancerGastric cancerBiliary tract cancerPancreatic cancer","Biliary tract neoplasms","Stomach neoplasms","Pancreatic neoplasms"],"disease":["Oxaliplatin","Peripheral Nervous System Diseases","Biliary Tract Neoplasms","Colorectal Neoplasms","Oxaliplatincolorectal Cancergastric Cancerbiliary Tract Cancerpancreatic Cancer","Pancreatic Neoplasms","Stomach Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2565376"],"location":["Thailand"],"study_start_month":["7"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Phase II Trial of capsaicin gel application for prevent oxaliplatin-induced peripheral neuropathy","description":"Interventions: 0.025% w/w Capsaicin gel;Experimental Drug;Capsaicin gel\nPrimary outcome(s): Grade D or more peripheral neuropathy - free rate (From Grade A to E) 4 weeks after last dose of chemotherapy Patient Neurotoxicity Questionnaire (Thai version)\nStudy Design: Non-randomized","dates":{"creation":"2015-07-15"},"accession":"2565376","cross_references":{"Thai Clinical Trials Register":["TCTR20150720002"]}}